|
US6046166A
(en)
*
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6037323A
(en)
*
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6004925A
(en)
*
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
MXPA01009893A
(es)
|
1999-04-01 |
2003-07-28 |
Esperion Therapeutics Inc |
Compuestos con eter, composiciones y usos de estos.
|
|
AUPQ846900A0
(en)
*
|
2000-06-29 |
2000-07-27 |
Aruba International Pty Ltd |
A vaccine
|
|
US7407662B2
(en)
*
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified viral particles with immunogenic properties and reduced lipid content
|
|
US7439052B2
(en)
*
|
2000-06-29 |
2008-10-21 |
Lipid Sciences |
Method of making modified immunodeficiency virus particles
|
|
US7407663B2
(en)
*
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified immunodeficiency virus particles
|
|
US20090017069A1
(en)
*
|
2000-06-29 |
2009-01-15 |
Lipid Sciences, Inc. |
SARS Vaccine Compositions and Methods of Making and Using Them
|
|
AU2007237157B2
(en)
*
|
2000-08-24 |
2009-04-09 |
The Regents Of The University Of California |
Peptides that ameliorate atherosclerosis
|
|
US7723303B2
(en)
*
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
|
US7199102B2
(en)
*
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7148197B2
(en)
*
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
|
US7166578B2
(en)
*
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US6664230B1
(en)
*
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
DE10051983A1
(de)
*
|
2000-10-20 |
2002-06-13 |
Beate Kehrel |
Inhibierung der pathogenen Wirkung oxidierter Proteine
|
|
DK1353666T3
(da)
*
|
2001-01-02 |
2013-10-14 |
Cleveland Clinic Foundation |
Myeloperoxidase, en risikoindikator for cardiovasculær sygdom
|
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US7217785B2
(en)
*
|
2001-05-09 |
2007-05-15 |
The Regents Of The University Of California |
Cysteine-containing peptides having antioxidant properties
|
|
US6991727B2
(en)
*
|
2001-06-25 |
2006-01-31 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
US20030127386A1
(en)
*
|
2001-06-25 |
2003-07-10 |
Bomberger David C. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
AU2002322284A1
(en)
*
|
2001-06-25 |
2003-01-08 |
Lipid Sciences, Inc. |
Systems and methods using multiple solvents for the removal of lipids from fluids
|
|
US20060060520A1
(en)
*
|
2001-06-25 |
2006-03-23 |
Bomberger David C |
Systems and methods using a solvent for the removal of lipids from fluids
|
|
US20030104350A1
(en)
*
|
2001-06-25 |
2003-06-05 |
Bomberger David C. |
Systems and methods using a solvent for the removal of lipids from fluids
|
|
US20050260256A1
(en)
*
|
2001-09-28 |
2005-11-24 |
Hill Knut R |
Methods and apparatus for extrusion of vesicles at high pressure
|
|
CA2460787A1
(en)
*
|
2001-09-28 |
2003-04-03 |
Esperion Therapeutics, Inc. |
Prevention and treatment of restenosis by local administration of drug
|
|
US20040009216A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Rodrigueza Wendi V. |
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
|
|
US6930085B2
(en)
*
|
2002-04-05 |
2005-08-16 |
The Regents Of The University Of California |
G-type peptides to ameliorate atherosclerosis
|
|
US20100204103A1
(en)
*
|
2002-05-08 |
2010-08-12 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
US7691965B2
(en)
*
|
2002-05-08 |
2010-04-06 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
JP2006507223A
(ja)
*
|
2002-05-17 |
2006-03-02 |
エスペリオン セラピューティクス，インコーポレイテッド |
脂質代謝異常疾患の治療方法
|
|
BR0310100A
(pt)
*
|
2002-05-17 |
2007-04-27 |
Esperion Therapeutics Inc |
métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
|
|
EP1545576A2
(de)
*
|
2002-07-30 |
2005-06-29 |
Esperion Therapeutics Inc. |
Verfahren zur verwendung von nichthumanem tierischem apoliprotein a-i protein
|
|
WO2004017946A1
(en)
*
|
2002-08-26 |
2004-03-04 |
Lipid Sciences, Inc. |
Treating alzheimers using delipidated protein particles
|
|
PT2404890T
(pt)
*
|
2003-01-23 |
2017-10-23 |
Esperion Therapeutics Inc |
Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas
|
|
MXJL05000046A
(es)
*
|
2003-04-22 |
2005-12-22 |
Avanir Pharmaceuticals |
Mediadores de transporte reverso de colesterol para el tratamiento de hipercolesterolemia.
|
|
US7393826B2
(en)
*
|
2003-07-03 |
2008-07-01 |
Lipid Sciences, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
|
JP2007527387A
(ja)
*
|
2003-07-03 |
2007-09-27 |
リピッド サイエンシーズ，インコーポレイテッド |
脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
|
|
US7459286B1
(en)
|
2003-10-22 |
2008-12-02 |
The Cleveland Clinic Foundation |
Assessing the risk of a major adverse cardiac event in patients with chest pain
|
|
US6960803B2
(en)
*
|
2003-10-23 |
2005-11-01 |
Silicon Storage Technology, Inc. |
Landing pad for use as a contact to a conductive spacer
|
|
ES2381551T3
(es)
|
2003-12-05 |
2012-05-29 |
The Cleveland Clinic Foundation |
Marcadores de riesgo para enfermedad cardiovascular
|
|
EP1699527A1
(de)
|
2004-01-02 |
2006-09-13 |
Advanced Cardiovascular Systems, Inc. |
Mit lipoprotein hoher dichte beschichtete medizinprodukte
|
|
JP2007531537A
(ja)
*
|
2004-04-06 |
2007-11-08 |
セダーズ−シナイ メディカル センター |
アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
|
|
WO2006020498A2
(en)
|
2004-08-11 |
2006-02-23 |
The Cleveland Clinic Foundation |
Therapeutic agents and methods for cardiovascular disease
|
|
CA2580501A1
(en)
*
|
2004-09-16 |
2006-03-30 |
The Regents Of The University Of California |
G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
|
|
WO2006049597A1
(en)
*
|
2004-10-27 |
2006-05-11 |
Avanir Pharmaceuticals |
Amino acid-derived compounds as modulators of the reverse cholesterol transport
|
|
KR20070089996A
(ko)
|
2004-12-06 |
2007-09-04 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
세동맥의 구조 및 기능의 개선 방법
|
|
WO2006069371A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Baylor College Of Medicine |
A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
|
|
US7759315B2
(en)
|
2005-03-09 |
2010-07-20 |
Csl Behring Ag |
Treatment of inflammatory conditions of the intestine
|
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
|
MX2007013430A
(es)
*
|
2005-04-29 |
2008-03-19 |
Univ California |
Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
|
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
KR101577554B1
(ko)
|
2005-08-22 |
2015-12-14 |
멜리어 파마슈티칼스 아이, 인코포레이티드 |
Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제
|
|
US20070254832A1
(en)
*
|
2006-02-17 |
2007-11-01 |
Pressler Milton L |
Methods for the treatment of macular degeneration and related eye conditions
|
|
WO2007137400A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Institut De Cardiologie De Montreal |
Method and compound for the treatment of valvular stenosis
|
|
US20080206142A1
(en)
*
|
2006-06-16 |
2008-08-28 |
Lipid Sciences, Inc. |
Novel Peptides That Promote Lipid Efflux
|
|
US20080199398A1
(en)
*
|
2006-06-16 |
2008-08-21 |
Brewer H Bryan |
Novel Peptides That Promote Lipid Efflux
|
|
US20080227686A1
(en)
*
|
2006-06-16 |
2008-09-18 |
Lipid Sciences, Inc. |
Novel Peptides that Promote Lipid Efflux
|
|
AU2007284801A1
(en)
|
2006-08-08 |
2008-02-21 |
The Regents Of The University Of Californina |
Salicylanilides enhance oral delivery of therapeutic peptides
|
|
WO2008039843A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Lipid Sciences, Inc. |
Novel peptides that promote lipid efflux
|
|
US8541236B2
(en)
*
|
2006-12-08 |
2013-09-24 |
University Of Washington |
Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
|
|
WO2008094905A2
(en)
*
|
2007-01-29 |
2008-08-07 |
Lipid Sciences, Inc. |
Encapsulated hdl mimetic peptides
|
|
CA3021932C
(en)
*
|
2007-01-31 |
2020-12-15 |
Jds Therapeutics, Llc |
Use of chromium histidinate for treatment of cardiometabolic disorders
|
|
CN101686686A
(zh)
*
|
2007-02-20 |
2010-03-31 |
梅里奥尔医药I公司 |
鉴别Lyn激酶激活剂的方法
|
|
ATE555801T1
(de)
|
2007-03-01 |
2012-05-15 |
Csl Ltd |
Behandlung von endothelialer dysfunktion bei diabetes-patienten
|
|
ES2579229T3
(es)
|
2007-03-13 |
2016-08-08 |
Jds Therapeutics, Llc |
Procedimientos y composiciones para la liberación sostenida de cromo
|
|
WO2009002867A2
(en)
|
2007-06-26 |
2008-12-31 |
Nutrition 21, Inc. |
Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
|
|
JP2010534668A
(ja)
*
|
2007-07-23 |
2010-11-11 |
メリオール・ディスカヴァリー・インコーポレイテッド |
Ｉｒｓ−１及びａｋｔを活性化する方法
|
|
AU2008296478B9
(en)
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
US8044021B2
(en)
|
2007-09-20 |
2011-10-25 |
Abbott Cardiovascular Systems Inc. |
Sustained release of apo A-I mimetic peptides and methods of treatment
|
|
US7985727B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Apo A-I mimetic peptides and methods of treatment
|
|
US9173890B2
(en)
|
2007-09-20 |
2015-11-03 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US8101565B2
(en)
|
2007-09-20 |
2012-01-24 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US7985728B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US8552184B2
(en)
*
|
2008-07-03 |
2013-10-08 |
Melior Pharmaceuticals I, Inc. |
Compounds and methods for treating disorders related to glucose metabolism
|
|
US8241861B1
(en)
|
2008-07-08 |
2012-08-14 |
Insilicos, Llc |
Methods and compositions for diagnosis or prognosis of cardiovascular disease
|
|
DK2355851T3
(en)
|
2008-11-10 |
2018-06-25 |
Arbutus Biopharma Corp |
Newly known lipids and compositions for release of therapeutic agents
|
|
US20120101148A1
(en)
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
|
EP2396017B1
(de)
|
2009-02-16 |
2015-07-01 |
Cerenis Therapeutics Holding SA |
Apolipoprotein-a-i mimetika
|
|
NZ594995A
(en)
|
2009-03-12 |
2013-06-28 |
Alnylam Pharmaceuticals Inc |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
|
|
CA2760776C
(en)
|
2009-05-05 |
2019-07-09 |
Alnylam Pharmaceuticals, Inc. |
Lipid compositions for the delivery of therapeutic agents
|
|
CA2764609C
(en)
|
2009-06-10 |
2018-10-02 |
Alnylam Pharmaceuticals, Inc. |
Improved cationic lipid of formula i
|
|
AP2015008874A0
(en)
|
2009-08-14 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
CN102753576A
(zh)
*
|
2009-09-30 |
2012-10-24 |
首尔大学教产学协力团 |
载脂蛋白a-1模拟肽以及包含其的用于治疗高血脂及高血脂相关疾病的治疗剂
|
|
US12419839B2
(en)
|
2009-10-09 |
2025-09-23 |
Signablok, Inc. |
Methods and compositions for targeted delivery of protein fragments
|
|
US10525152B2
(en)
|
2009-10-09 |
2020-01-07 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
|
US10894098B2
(en)
|
2012-04-09 |
2021-01-19 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
|
CA2783372C
(en)
|
2009-12-07 |
2019-07-16 |
Muthiah Manoharan |
Compositions for nucleic acid delivery
|
|
AU2010330814B2
(en)
|
2009-12-18 |
2017-01-12 |
Acuitas Therapeutics Inc. |
Methods and compositions for delivery of nucleic acids
|
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
US20130137628A1
(en)
|
2010-05-11 |
2013-05-30 |
Esperion Therapeutics, Inc. |
Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
|
|
WO2011150300A1
(en)
|
2010-05-28 |
2011-12-01 |
Melior Pharmaceuticals I, Inc. |
Prevention of pancreatic beta cell degeneration
|
|
CA2800401C
(en)
|
2010-06-03 |
2020-09-15 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
RU2013111678A
(ru)
|
2010-08-30 |
2014-10-10 |
Ф. Хоффманн-Ля Рош Аг |
Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение
|
|
CN110123830A
(zh)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
|
JP5902197B2
(ja)
|
2011-01-11 |
2016-04-13 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
|
|
HRP20190138T1
(hr)
|
2011-02-07 |
2019-03-22 |
Cerenis Therapeutics Holding Sa |
Lipoproteinski kompleksi i njihova proizvodnja i uporaba
|
|
AU2012223282B2
(en)
|
2011-03-01 |
2017-02-02 |
Nutrition 21, Llc |
Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
|
|
AU2012315965A1
(en)
|
2011-09-27 |
2014-04-03 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted PEGylated lipids
|
|
CN107007608B
(zh)
|
2011-12-12 |
2021-04-23 |
梅里奥尔医药I公司 |
I型和ii型糖尿病的治疗
|
|
CN103073646A
(zh)
*
|
2012-03-13 |
2013-05-01 |
华中科技大学 |
一种运载蜂毒肽的多肽、运载蜂毒肽的纳米颗粒及其应用
|
|
US10017551B2
(en)
|
2013-03-15 |
2018-07-10 |
The Regents Of The University Of California |
Peptides having reduced toxicity that stimulate cholesterol efflux
|
|
EP2853259A1
(de)
|
2013-09-30 |
2015-04-01 |
Université Pierre et Marie Curie (Paris 6) |
Rekonstituierte hochdichte Lipoproteinzusammensetzung und Verwendungen davon
|
|
KR20170003611A
(ko)
|
2014-05-02 |
2017-01-09 |
세레니스 쎄라퓨틱스 홀딩 에스에이 |
Ｈｄｌ 요법 마커
|
|
WO2016011049A2
(en)
*
|
2014-07-14 |
2016-01-21 |
Schwendeman Anna |
Compositions and methods for disease treatment using nanoparticle delivered compounds
|
|
AU2015298263B2
(en)
|
2014-07-31 |
2020-05-14 |
Anji Pharmaceuticals, Inc. |
ApoE mimetic peptides and higher potency to clear plasma cholesterol
|
|
US10307491B2
(en)
|
2015-01-30 |
2019-06-04 |
The Regents Of The University Of Michigan |
Liposomal particles comprising biological molecules and uses thereof
|
|
WO2016149191A1
(en)
|
2015-03-13 |
2016-09-22 |
Esperion Therapeutics, Inc. |
Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
|
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
|
EP4537906A3
(de)
|
2015-03-25 |
2025-08-20 |
The Regents of the University of Michigan |
Zusammensetzungen und verfahren zur abgabe von biomakromolekülwirkstoffen
|
|
AU2017217466A1
(en)
|
2016-02-11 |
2018-08-23 |
Nutrition 21, Llc |
Chromium containing compositions for improving health and fitness
|
|
EP3471778A4
(de)
|
2016-06-20 |
2020-02-19 |
The Regents of The University of Michigan |
Zusammensetzungen und verfahren zur abgabe von biomakromolekülwirkstoffen
|
|
MX387305B
(es)
|
2017-04-10 |
2025-03-18 |
Melior Pharmaceuticals I Inc |
Tratamiento de adipocitos
|
|
ES2984285T3
(es)
|
2017-08-10 |
2024-10-29 |
Abionyx Pharma Sa |
Cargómeros
|
|
EP3714039B1
(de)
|
2017-11-22 |
2025-03-12 |
HDL Therapeutics, Inc. |
Verfahren zum primen von fluidkreisläufen eines plasmabearbeitungssystems
|
|
AU2018396009A1
(en)
|
2017-12-28 |
2020-07-16 |
Hdl Therapeutics, Inc. |
Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
|
|
US12344578B2
(en)
|
2019-06-21 |
2025-07-01 |
Esperion Therapeutics, Inc. |
Salt forms of bempedoic acid and methods for using the same
|
|
US20240033322A1
(en)
|
2020-04-16 |
2024-02-01 |
Abionyx Pharma Sa |
Methods for treating acute conditions using lipid binding protein-based complexes
|
|
EP4221686A2
(de)
|
2020-10-01 |
2023-08-09 |
Abionyx Pharma SA |
Zusammensetzungen mit lipidbindenden komplexen auf proteinbasis zur verwendung zur behandlung von augenerkrankungen
|
|
AU2021361055A1
(en)
*
|
2020-10-16 |
2023-06-22 |
Cedars-Sinai Medical Center |
Microbiome-derived gaseous sample collection system and methods
|
|
WO2022219413A1
(en)
|
2021-04-15 |
2022-10-20 |
Abionyx Pharma Sa |
Use of lipid binding protein-based complexes in organ preservation solutions
|
|
JP2025511845A
(ja)
|
2022-04-06 |
2025-04-16 |
アビオニクス ファーマ エスエー |
脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
|
|
AU2023251245A1
(en)
|
2022-04-06 |
2024-11-14 |
Abionyx Pharma Sa |
Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
|
|
IL317448A
(en)
|
2022-06-10 |
2025-02-01 |
Abionyx Pharma Sa |
Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
|
|
JP2025519606A
(ja)
|
2022-06-10 |
2025-06-26 |
アビオニクス ファーマ エスエー |
脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
|
|
JP2026504047A
(ja)
|
2023-01-13 |
2026-02-03 |
アビオニクス ファーマ エスエー |
脂質結合タンパク質分子療法
|
|
WO2025093929A1
(en)
|
2023-10-31 |
2025-05-08 |
Abionyx Pharma Sa |
Lipid binding protein molecule therapy
|